8-K: Tonix Pharmaceuticals Announces Positive Data for TNX-102 SL in Long COVID and Acute Stress Reaction Studies

Tonix Pharmaceuticals reported encouraging results for its TNX-102 SL product in treating fatigue related to Long COVID and is initiating a trial for acute stress reaction following motor vehicle collisions.

Summary

• Tonix Pharmaceuticals presented data from two poster presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.
• The first poster detailed results from a Phase 2 study of TNX-102 SL in fibromyalgia-type Long COVID, showing a significant effect size of 0.5 in improving fatigue.
• The study also showed consistent activity across secondary measures like sleep quality, cognitive function, disability, and Patient Global Impression of Change.
• However, the study did not meet its primary endpoint of multi-site pain reduction at Week 14.
• The second poster outlined the design of the OASIS trial, which will evaluate TNX-102 SL for reducing acute stress reaction (ASR) and preventing acute stress disorder (ASD) and posttraumatic stress disorder (PTSD) in civilians after motor vehicle collisions.
• The first patient in the OASIS trial is expected to enroll in the second quarter of 2024.
• Tonix is preparing for a New Drug Application (NDA) submission for TNX-102 SL (branded Tonmya) for the management of fibromyalgia in the second half of 2024.

Sentiment

Score: 7

Explanation: The document presents positive clinical data for TNX-102 SL in Long COVID and outlines a new trial for acute stress reaction, indicating progress in the company's pipeline. However, the failure to meet the primary endpoint in the Long COVID study and the inherent risks in drug development temper the overall sentiment.

Positives

• TNX-102 SL showed a significant improvement in fatigue with an effect size of 0.5 in Long COVID patients.
• The drug demonstrated consistent activity across multiple secondary measures, indicating a broad positive impact.
• The OASIS trial has the potential to address a critical unmet need for early intervention in acute stress reaction.
• TNX-102 SL was well tolerated with an adverse event profile comparable to prior studies and no new safety signals observed.
• The company is progressing towards an NDA submission for TNX-102 SL for fibromyalgia.

Negatives

• The Phase 2 study of TNX-102 SL in Long COVID did not meet its primary endpoint of multi-site pain reduction at Week 14.
• There was a substantial placebo response in pain magnitude measurements.

Risks

• The company faces risks related to obtaining FDA clearances or approvals.
• There are risks related to the successful marketing of any of their products.
• The timing and progress of clinical development of product candidates are uncertain.
• The company has a need for additional financing.
• There are uncertainties of patent protection and litigation.
• There are uncertainties of government or third party payor reimbursement.
• The company has limited research and development efforts and dependence upon third parties.
• The company faces substantial competition.

Future Outlook

Tonix plans to submit an NDA for TNX-102 SL (Tonmya) for fibromyalgia in the second half of 2024 and is initiating the OASIS trial to evaluate TNX-102 SL for acute stress reaction.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated that the results support the idea that Long COVID symptoms are partly driven by central nervous system mechanisms.
• Dr. Lederman also mentioned that the study is motivated by the observation that the symptoms of ASR and PTSD are similar and by the hypothesis that TNX-102 SLs effect on sleep quality may reduce ASR symptoms.

Industry Context

The announcement highlights Tonix's efforts to address unmet needs in both chronic pain conditions like fibromyalgia and emerging conditions like Long COVID, as well as acute stress reactions, which are areas of significant medical interest and potential market opportunity.

Comparison to Industry Standards

• The effect size of 0.5 for fatigue improvement in the Long COVID study is considered clinically meaningful and suggests a potentially competitive advantage compared to other treatments.
• The focus on early intervention for acute stress reaction with TNX-102 SL is innovative, as there are currently no medications available at or near the point of care for this condition.
• The company's progress towards an NDA submission for TNX-102 SL for fibromyalgia aligns with industry timelines for drug development and regulatory approval.

Stakeholder Impact

• Shareholders may view the positive clinical data and progress towards NDA submission favorably.
• Patients with fibromyalgia and Long COVID may benefit from the potential new treatment options.
• Healthcare providers may have new tools for managing these conditions.
• Employees of Tonix may be impacted by the progress of the clinical trials and regulatory submissions.

Next Steps

• Enrollment of the first patient in the OASIS trial is expected in the second quarter of 2024.
• Tonix will have a Type B pre-NDA meeting with the FDA in the second quarter of 2024.
• The company plans to submit an NDA for TNX-102 SL (Tonmya) for fibromyalgia in the second half of 2024.

Key Dates

Keywords

TNX-102 SL, Fibromyalgia, Long COVID, Acute Stress Reaction, PTSD, Clinical Trial, NDA, Tonmya, ASCP, OASIS Trial